29 Sep, 2021 RNAi Therapeutics Platform Progress at OTS 2021 Annual Meeting
We presented progress on our RNAi therapeutics platform efforts at the Oligonucleotide Therapeutics Society (OTS) 2021 Annual Meeting.
Harnessing RNAi for a New Class of Medicines – John Maraganore
Expanding the Reach of RNAi Therapeutics – Kirk Brown
Development of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 – Pushkal Garg
Dose-Related and Prolonged Reductions in Blood Pressure with a RNAi Therapeutic Targeting Angiotensinogen in Hypertensive Patients: Interim Results from a Phase 1 Study with Zilebesiran (ALN-AGT01) – Stephen Huang